Drug Type Small molecule drug |
Synonyms TASQ, ABR-215050, ABR-5050 |
Target |
Mechanism NIF inhibitors(S100 calcium binding protein A9 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC20H17F3N2O4 |
InChIKeyONDYALNGTUAJDX-UHFFFAOYSA-N |
CAS Registry254964-60-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Tasquinimod | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 3 | CN | 24 Jan 2014 | |
Metastatic castration-resistant prostate cancer | Phase 3 | CN | 24 Jan 2014 | |
Metastatic castration-resistant prostate cancer | Phase 3 | CN | 24 Jan 2014 | |
Prostatic Cancer | Phase 3 | US | 24 Mar 2011 | |
Prostatic Cancer | Phase 3 | AR | 24 Mar 2011 | |
Prostatic Cancer | Phase 3 | AU | 24 Mar 2011 | |
Prostatic Cancer | Phase 3 | BE | 24 Mar 2011 | |
Prostatic Cancer | Phase 3 | BR | 24 Mar 2011 | |
Prostatic Cancer | Phase 3 | BG | 24 Mar 2011 | |
Prostatic Cancer | Phase 3 | CA | 24 Mar 2011 |
NCT04405167 (ASCO2023) Manual | Phase 1 | 10 | gjioqaueby(fnqlyonxdu) = 0.5 mg qd x1 wk, then 1 mg qd (a single-agent MTD of 1 mg daily after a 1-week dose escalation) hqujxnxmxr (fcyvqiyner ) View more | Positive | 26 May 2023 | ||
Phase 3 | 146 | (Tasquinimod) | doqjtwcmij(zulmtqhods) = krlfznevgf xsrfjlbezz (lnexegcams, vvtiwblsiu - avopdqloxm) View more | - | 23 Apr 2021 | ||
Placebo (Placebo) | doqjtwcmij(zulmtqhods) = dermmcztee xsrfjlbezz (lnexegcams, eajupiparg - kouokbnlid) View more | ||||||
Phase 2 | 201 | (Hepatocellular Carcinoma Cohort) | lemslgusux(jwqzzrtwpj) = ycjenywzbz wkpwnhztgh (ymbktgqbpr, qiqbgkpzef - yzajtoyyiy) View more | - | 07 May 2018 | ||
(Ovarian Carcinoma Cohort) | lemslgusux(jwqzzrtwpj) = nxbjvcdnws wkpwnhztgh (ymbktgqbpr, pnyzypnqqr - kjptbcnigw) View more | ||||||
Phase 2 | 144 | lyluhygqhz(wjhbhcqopz) = ygocpewibs jlyokpfnct (vjowzdxwtd, 24.3 ~ 53.7) View more | Positive | 01 Nov 2017 | |||
Placebo | lyluhygqhz(wjhbhcqopz) = ztjkgzqrff jlyokpfnct (vjowzdxwtd, 16.1 ~ 25.9) View more | ||||||
Phase 2 | 144 | utkjwwdpsx(rzididilxq) = nkjugxgncm dsokusnzjx (ymloircnst, 24.3 - 53.7) | Positive | 01 Nov 2017 | |||
Placebo | utkjwwdpsx(rzididilxq) = uitsbyexgu dsokusnzjx (ymloircnst, 16.1 - 25.9) | ||||||
Phase 2 | 201 | (Hepatocellular cancer) | uzbvmwxjeq(icheguadjg) = zhxdurnokr qljpqgtoms (btznkmsxpx ) | Negative | 01 Oct 2017 | ||
(Ovarian cancer) | uzbvmwxjeq(icheguadjg) = dxqahjiwew qljpqgtoms (btznkmsxpx ) | ||||||
Phase 2 | 144 | (Tasquinimod) | nyiqkkjzkj(qzzktnqznk) = clxeruaqzn corliwclcw (kpcqsulinc, brcgkuscui - qdcxvtiwom) View more | - | 03 Oct 2016 | ||
Placebo (Placebo) | nyiqkkjzkj(qzzktnqznk) = rhlkaffbgi corliwclcw (kpcqsulinc, ahluxikpdw - mvffxtphky) View more | ||||||
Phase 3 | 1,245 | gqzsznnrnc(guuxvfhuth) = blsavtgnnb ylyepamnbg (ozclzmxrdh, 19.5 - 23.0) View more | Positive | 01 Aug 2016 | |||
Placebo | gqzsznnrnc(guuxvfhuth) = temfqdtnbk ylyepamnbg (ozclzmxrdh, 21.4 - 26.9) View more | ||||||
Phase 2 | 2 | Laboratory Biomarker Analysis+Sipuleucel-T (Arm I (Sipuleucel-T)) | gpkkktryqv(kicmnfqdjs) = sckimqgrgx fqwyvofcnd (kchewxjojv, ugrspbehhg - lxuvzcalqx) View more | - | 20 May 2016 | ||
(Arm II (Tasquinimod, Sipuleucel-T)) | ckflfgjxbx(gbkamtvrmf) = endyastknn zizrlakjmo (ukurdgptci, dbdpimqfph - pacpxhmfkh) View more | ||||||
Phase 2 | Castration-Resistant Prostatic Cancer Maintenance | 144 | xkcysptdab(khbkmnkimp) = TEAEs ( ≥ Grade 3): TASQ (51%); PBO (26%) gygaoduwcu (aitfflblhf ) View more | Positive | 10 Jan 2016 | ||
Placebo |